Navigation Links
ACP pledges support for Medicare improvements for Patients and Providers Act of 2008
Date:6/9/2008

Washington The 125,000-member American College of Physicians (ACP) today pledged its support for enactment of S. 3101, the Medicare Improvements for Patients and Providers Act of 2008.

"The College is able to enthusiastically support S. 3101 because it addresses and incorporates three of our top legislative priorities," ACP President Jeffrey P. Harris, MD, FACP, wrote Senator Max Baucus (D-MT), chairman of the Senate Finance Committee.

Writing on behalf of the largest medical specialty society and second largest physician membership organization in the U.S., Dr. Harris said, "I am writing to congratulate you" on introduction of the bill because:

  • The Medicare Sustainable Growth Rate (SGR) physician payment cuts will be replaced by 18 months of positive updates.

  • Medicare payment policies will be improved to address the growing crisis in access to primary care services.

  • It includes increased funding for the Medicare medical home demonstration project and authorizes the Secretary to expand it if the demo achieves measurable improvements in patient care.

"We had three top legislative priorities for the Medicare bill, all of which are included in S. 3101: 18 months of positive updates instead of the SGR cuts, improvements in payments for primary care services (change in budget neutrality adjustment from work Relative Value Units (RVUs) to the conversion factor, increases for primary care services in Physician Scarcity Areas (PSAs), and funding and authority for the medical home demo, and all of these are included in S. 3101," noted Dr. Harris. "ACP policy also supports the benefit improvements in the bill: coverage for preventive services and phasing out of the higher mental health co-pay."

In his letter to Senator Baucus, Dr. Harris also congratulated bill co-sponsors Senators Olympia Snowe (R-ME), Gordon Smith (R-OH) and Jay Rockefeller (D-VA), who provide an important bip
'/>"/>

Contact: David Kinsman
dkinsman@acponline.org
202-261-4554
American College of Physicians
Source:Eurekalert

Page: 1 2

Related medicine news :

1. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
2. DuPont Pledges $250,000 to Nature Conservancy for Water Quality Initiative
3. Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings
4. Obama Pledges Major Expansion of AIDS and Global Poverty Programs
5. DuPont Pledges $1 Million to World Food Prize
6. Charles Lafitte Foundation Pledges $1 Million to the American Cancer Societys Hope Lodge
7. Racing Professional Steve Marcus Pledges Season BMW Proceeds to Morris Animal Foundations Meishas Hope Fund
8. HIV therapy in pregnancy-data support WHO recommendations
9. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
10. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
11. Family-based treatment more effective than supportive psychotherapy in treating bulimia
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 2Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 3Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 4Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 5Veran Medical Receives FDA Clearance to Market Electromagnetic Navigated Bronchoscopy Product: The SPiN Drive(TM) System 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 1The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 2The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 3The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 4Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 1Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 2Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 3Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 4Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 1Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 2Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 3Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 4
Other Medicine Technology:Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 3Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 4Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 5Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 6Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 7Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 8Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 9Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 10Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 11Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 12